# Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07714447/  
OnCo record `nct07714447` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07714447 by Sun Yat-sen University, with a registry enrolment figure of 91 participants, started 2026-11-30 and due to reach its primary completion in 2029-02-01. Interventions recorded: Arm1; Arm 2; Arm 3. Conditions listed: CRC (Colorectal Cancer); BRAF. Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "* Patients with metastatic colorectal cancer confirmed by histology or cytology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07714447
- Phase: 2
- Setting: Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer: a Multicentre, Multicohort, Phase 2 Trial.
- Sponsor: Sun Yat-sen University
- Enrolled: 91

## Sources

- ClinicalTrials.gov NCT07714447: https://clinicaltrials.gov/study/NCT07714447

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07714447.json